All In Biotech

Drug Trial Radar · NCT00150800

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

668

Actual

Start

Jan 2006

Primary completion

Sep 2017

Study completion Sep 2017

Sponsor

Lead sponsor
UCB PHARMA Inc. (US)UCB
Sponsor type
Industry
First posted
Sep 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.

Conditions

  • Epilepsy

Interventions

  • BrivaracetamDrug

    * Active Substance: Brivaracetam * Pharmaceutical Form: Tablet * Concentration: 10 mg and 25 mg * Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
  2. Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
  3. Percentage of Participants With a Serious Adverse Event (SAE) During the Study PeriodTime frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)

Locations

100 sites in 6 countries. Site status is shown where the registry gives one.

  • N01199 1051

    Phoenix, Arizona

  • N01199 1362

    Phoenix, Arizona

  • N01199 1374

    Tucson, Arizona

  • N01199 1050

    Little Rock, Arkansas

  • N01199 1078

    Fresno, California

  • N01199 1392

    Newport Beach, California

  • N01199 1087

    San Francisco, California

  • N01199 1368

    San Francisco, California

  • N01199 1396

    Atlanta, Georgia

  • N01199 1385

    Augusta, Georgia

  • N01199 1356

    Chicago, Illinois

  • N01199 1388

    Springfield, Illinois

  • N01199 1375

    Wichita, Kansas

  • N01199 1364

    Lexington, Kentucky

  • N01199 1380

    Louisville, Kentucky

  • N01199 1052

    Paducah, Kentucky

  • N01199 1083

    Ruston, Louisiana

  • N01199 1373

    Baltimore, Maryland

  • N01199 1086

    Bethesda, Maryland

  • N01199 1077

    Burlington, Massachusetts

  • N01199 1391

    Detroit, Michigan

  • N01199 1395

    Detroit, Michigan

  • N01199 1071

    Grand Rapids, Michigan

  • N01199 1389

    Saint Paul, Minnesota

  • N01199 1079

    Tupelo, Mississippi

  • N01199 1360

    Chesterfield, Missouri

  • N01199 1352

    St Louis, Missouri

  • N01199 1069

    Great Falls, Montana

  • N01199 1062

    Toms River, New Jersey

  • N01199 1053

    New York, New York

  • N01199 1365

    Rochester, New York

  • N01199 1366

    Cincinnati, Ohio

  • N01199 1054

    Columbus, Ohio

  • N01199 1359

    Portland, Oregon

  • N01199 1055

    Philadelphia, Pennsylvania

  • N01199 1059

    Philadelphia, Pennsylvania

  • N01199 1081

    Greenville, South Carolina

  • N01199 1061

    Nashville, Tennessee

  • N01199 1084

    Dallas, Texas

  • N01199 1394

    Dallas, Texas

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.